This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-weekly cycles of treatment with either: 1) Xeloda, Avastin and oxaliplatin; or 2) Xeloda, Avastin and irinotecan. After 9 cycles, patients continued to receive maintenance treatment with Xeloda + Avastin. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.

Inclusion Criteria:

• Adult patients, ≥18 years of age
• Histologically confirmed adenocarcinoma of colon or rectum, with unresectable metastatic or locally advanced disease
• ≥1 measurable target lesion
• Ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

Exclusion Criteria:

• Prior systemic therapy for advanced or metastatic disease
• History of another malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of the cervix
• Clinically significant cardiovascular disease
• Current or recent use of full dose oral warfarin or full dose parenteral anticoagulants or thrombolytic agents
• Chronic daily treatment with >325 mg/day aspirin

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.